Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diosmin Combinations for OHSS Prevention in High-Risk Women
NCT06333691Completed
- Sponsor
- Minia University
- Start
- Oct 2022
- Primary completion
- Feb 2024
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Randomised, single-blind trial of diosmin in ovarian hyperstimulation syndrome (OHSS) (3 arms), sponsored by Minia University. Primary endpoint: Incidence rate of moderate to severe Ovarian Hyperstimulation Syndrome at 3 months. Started Oct 2022; status: completed.
02
Drugs
diosmin
03
Conditions
ovarian hyperstimulation syndrome (OHSS)
Beyond the preview
Go deeper on NCT06333691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06333691.